Related Experiment Video
Updated: Jul 7, 2025
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in
Brittany A Comunale1, Robin J Larson2,3, Erin Jackson-Ward1,4
1Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Background:
As long as COVID-19 endures, viral surface proteins will keep changing and new viral strains will emerge, rendering prior vaccines and treatments decreasingly effective. To provide durable targets for preventive and therapeutic agents, there is increasing interest in slowly mutating viral proteins, including non-surface proteins like RdRp.
Methods:
A scoping review of studies was conducted describing RdRp in the context of COVID-19 through MEDLINE/PubMed and EMBASE. An iterative approach was used with input from content experts and three independent reviewers, focused on studies related to either RdRp activity inhibition or RdRp mechanisms against SARS-CoV-2.
Results:
Of the 205 records screened, 43 studies were included in the review. Twenty-five evaluated RdRp activity inhibition, and eighteen described RdRp mechanisms of existing drugs or compounds against SARS-CoV-2. In silico experiments suggested that RdRp inhibitors developed for other RNA viruses may be effective in disrupting SARS-CoV-2 replication, indicating a possible reduction of disease progression from current and future variants. In vitro, in vivo, and human clinical trial studies were largely consistent with these findings.
Conclusions:
Future risk mitigation and treatment strategies against forthcoming SARS-CoV-2 variants should consider targeting RdRp proteins instead of surface proteins.
Insights
Targeting the RNA-dependent RNA polymerase (RdRp) offers a durable strategy against evolving COVID-19 variants. Inhibiting RdRp may reduce disease progression from current and future SARS-CoV-2 strains.
Area of Science:
- Virology
- Drug Discovery
- Immunology
Background:
- COVID-19 variants continually emerge due to mutating surface proteins, reducing vaccine and treatment efficacy.
- Non-surface viral proteins, such as RNA-dependent RNA polymerase (RdRp), mutate slowly, offering more stable therapeutic targets.
Purpose of the Study:
- To review existing research on RNA-dependent RNA polymerase (RdRp) in SARS-CoV-2.
- To assess the potential of targeting RdRp for developing durable COVID-19 therapeutics and preventive agents.
Main Methods:
- A scoping review of MEDLINE/PubMed and EMBASE databases was performed.
- Studies focused on RdRp activity inhibition or mechanisms against SARS-CoV-2 were iteratively selected.
- Content experts and three independent reviewers contributed to the study selection process.
Main Results:
- 43 studies were included, with 25 evaluating RdRp inhibition and 18 detailing RdRp mechanisms.
- In silico studies suggest RdRp inhibitors for other RNA viruses may inhibit SARS-CoV-2 replication.
- In vitro, in vivo, and clinical data largely support the efficacy of RdRp inhibition against SARS-CoV-2.
Conclusions:
- Targeting the slowly mutating RdRp protein is a promising strategy for future COVID-19 risk mitigation.
- RdRp inhibition could provide effective treatments against current and emerging SARS-CoV-2 variants.
- Future therapeutic and preventive strategies should prioritize RdRp over rapidly mutating surface proteins.
Related Concept Videos
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
00:58Eukaryotic RNA Polymerases
All three eukaryotic RNAPs require specific transcription factors, of which the...
00:43Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
02:28Leaky Scanning
01:47Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
02:15Experimental RNAi